Clinical Trials in Maryland

Showing 3621-3640 of 11,119 trials

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

NCT02514083

This is a pilot phase 2 study investigating the safety and efficacy of ibrutinib combined with short-course fludarabine in previously untreated CLL patients. Ibrutinib will be given daily until disease progression or intolerable side effects occur. Fludarabine will be given in cycles 3 and 4. The primary efficacy endpoint is the rate of complete response after 6 cycles or 24 weeks. The primary safety endpoint is the rate of treatment discontinuation after 6 cycles or 24 weeks.

Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

National Heart, Lung, and Blood Institute (NHLBI)29 participantsStarted Dec 2015

Bethesda, Maryland, United States

COMPLETEDPhase 217 miles

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

NCT02177695

The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or "COXEN" may predict a patient's response to chemotherapy before surgery.

Bladder Cancer

SWOG Cancer Research Network237 participantsStarted Aug 2014

Birmingham, Alabama, United States • Fairbanks, Alaska, United States • Phoenix, Arizona, United States +563 more locations

A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

S1314, Co-expression Extrapolation (COXEN) Program to Predict Chemotherapy Response in Patients With Bladder Cancer

Find Trials by Condition in Maryland

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA

Transcutaneous Electroacupuncture for Gastrointestinal Motility Disorders

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients (2-<18 Years Old) With Iron Overload

Phase 1, First-in-human Study of Oral TP-1287 in Patients with Advanced Solid Tumors

Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Mg in Patients With Primary Biliary Cholangitis

A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine

The PREDICT Registry:

Viz HCM (ECG Assist) Utilization Workflow Pilot

A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Participants With Advanced Solid and Hematologic Cancers

First-in-Human Study of EOS100850 (Inupadenant) in Patients with Cancer

An Open-Label Extension Study for Patients With Duchenne Muscular Dystrophy Who Participated in Studies of SRP-5051 (Vesleteplirsen)

Randomized Controlled Trial for Vestibular Treatment in Concussion

Air Optix® Night and Day® Aqua Continuous Wear

Long-term Safety of Lumacaftor/Ivacaftor in Participants With Cystic Fibrosis Who Are Homozygous for F508del and 12 to <24 Months of Age at Treatment Initiation

A Randomized Phase 2 Trial of TAS-114 in Combination With S-1 Versus S-1

Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours

Target Controlled Infusion Using Propofol and Remifentanil for Moderate Sedation in Dentistry